Entecavir Therapy in Turkish Adult Patients with Chronic Hepatitis B: One-Year Results from Izmir Province, Turkey

AUTHORS

Sukran Kose 1 , * , Melda Turken Ulusoy 2 , Gulgun Akkoclu 2 , Ayhan Gozaydin 2

1 Tepecik Research and Training Hospital,Clinic of Clinical Microbiology and Infectious Diseases, [email protected], Izmir, Turkey

2 Tepecik Research and Training Hospital,Clinic of Clinical Microbiology and Infectious Diseases, Izmir, Turkey

How to Cite: Kose S, Ulusoy M, Akkoclu G, Gozaydin A. Entecavir Therapy in Turkish Adult Patients with Chronic Hepatitis B: One-Year Results from Izmir Province, Turkey, Hepat Mon. Online ahead of Print ; 10(3):183-187.

ARTICLE INFORMATION

Hepatitis Monthly: 10 (3); 183-187
Article Type: Research Article
Received: February 15, 2010
Accepted: May 7, 2010

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: In the present study, we aimed to present the initial results of chronic hepatitis B patients who received entecavir (ETV) therapy in our hospital in Izmir, Turkey.

Methods: A total of 52 patients were enrolled in the study. ETV was given in a dosage of 0.5 mg/day and 1 mg/day to 50 patients without Lamivudine/Adefovir (LAM/ADV) resistance and to 2 patients with LAM resistance, respectively. ETV was given in a dose of 0.5 mg/day every three days to one patient with a renal transplant. The treatment duration was 48 weeks.

Results: Out of a total of 52 patients, 23 (44.23%) were hepatitis B e antigen (HBeAg)-positive, and 29 (55.77%) of them were HBeAg-negative. In 29 HBeAg-negative patients, early biochemical and virological responses were 82.6% and 100%, respectively. These responses were 97% and 79.3% in the 12th month. In HBeAg-positive patients, early biochemical and virological responses were found to be 78.3% and 82.6%, respectively. They were 100% and 52.2% in the 12th month. HBeAg seroconversion developed in 4.5% of HBeAg-positive patients.

Conclusions: According to our one-year ETV treatment results, both HBeAg-negative and -positive patients had high biochemical and virological response rates. Their HBeAg seroconversion rate was 4.5%. In conclusion, more studies of longer duration are needed to understand the required duration of treatment, to assess its long-term effectiveness, and to check the resistance and side effects of ETV. There is also a need to have late-phase results after treatment.

Keywords

Hepatitis B Treatment Entecavir

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: